Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study

Journal of Clinical Psychopharmacology

Volumn 31, Issue 1, 2011, Pages 92-97

  Sakolsky, Dara J ^a   Perel, James M ^a   Emslie, Graham J ^b   Clarke, Gregory N ^c   Wagner, Karen Dineen ^d   Vitiello, Benedetto ^e   Keller, Martin B ^f   Birmaher, Boris ^a   Asarnow, Joan Rosenbaum ^g   Ryan, Neal D ^a   McCracken, James T ^g   Strober, Michael J ^g   Iyengar, Satish ^h   Porta, Giovanna ^a   Brent, David A ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c CENTER FOR HEALTH RESEARCH   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^f BROWN UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

adolescents; drug exposure; major depressive disorder; optimization; plasma concentration

Indexed keywords

CITALOPRAM; DESVENLAFAXINE; ESCITALOPRAM; FLUOXETINE; NORFLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADOLESCENT; ANGER; APATHY; APPETITE DISORDER; ARTICLE; CARDIOVASCULAR SYMPTOM; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ASSESSMENT; COGNITIVE THERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; EYE DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; IRRITABILITY; LETHARGY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOUTH DISEASE; MUSCULOSKELETAL DISEASE; NOSE DISEASE; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; SIDE EFFECT; SKIN MANIFESTATION; SLEEP DISORDER; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE;

ADOLESCENT; AGE FACTORS; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUOXETINE; HUMANS; MALE; TREATMENT OUTCOME;

EID: 78651271814     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318204b117     Document Type: Article

References (26)

1. Birmaher B, Brent D, Work Group on Quality Issues. Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry. 2007;46:1503-1526.
2. Bridge J, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007;297:1683-1696.
3. Brent DA, Emslie GJ, Clarke GN, et al. Switching to venlafaxine or another SSRI with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA. 2008;299:901-913.
4. Hiemke C. Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises? Eur Arch Psychiatry Clin Neurosci. 2008;258(suppl 1):21-27.
5. Reis M, Aberg-Wistedt A, Agren H, et al. Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. Human Psychopharmacology. 2004;19:283-291.
6. Amsterdam JD, Fawcett J, Quitkin FM, et al. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry. 1997;7:963-969.
7. Gex-Fabry M, Gervasoni N, Eap CB, et al. Time course of response to paroxetine: influence of plasma level. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:892-900.
8. Waldschmitt C, Vogel F, Pfuhlmann B, et al. Duloxetine serum concentrations and clinical effects. Data from a therapeutic drug monitoring (TDM) survey. Pharmacopsychiatry. 2009;42:189-193.
9. Gex-Fabry M, Balant-Gorgia AE, Balant LP, et al. Time course of clinical response to venlafaxine: relevance of plasma level and chirality. Eur J Clin Pharmacol. 2004;59:883-891.
10. Charlier C, Pinto E, Ansseau M, et al. The relationship between dose, plasma, concentration and clinical response in depressive patients. J Psychopharmacol. 2002;16:369-372.
11. Puig-Antich J, Perel JM, Lupatkin W, et al. Imipramine in prepubertal major depressive disorders. Arch Gen Psychiatry. 1987;44:81-89.
12. Daviss WB, Perel JM, Brent DA, et al. Acute antidepressant response and plasma levels of bupropion and metabolites in a pediatric-aged sample: an exploratory study. Ther Drug Monit. 2006;28:190-198.
13. Findling RL, McNamara NK, Stansbrey RJ, et al. The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression. J Child Adolesc Psychopharmacol. 2006;16:131-145.
14. Mehler-Wex C, Kolch M, Kirchheiner J, et al. Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy. Child and Adolescent Psychiatry and Mental Health. 2009;3:14-18.
15. Axelson DA, Perel JM, Birmaher B, et al. Sertraline pharmacokinetics and dynamics in adolescents. J Am Acad Child Adolesc Psychiatry. 2002;41:1037-1044.
16. Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an 11C]DASB positron emission tomography study. Am J Psychiatry. 2004;161:826-835.
17. Guy W. ECDEU Assessment Manual for Psychopharmacology. 2nd ed. Washington, DC: US Government Printing Office; 1976.
18. Poznanski EO, Freeman LN, Mokros HB. Children's Depression Rating ScaleVRevised. Psychopharmacol Bull. 1984;21:979-989.
19. Klein RG, Abikoff H, Barkley RA. Clinical trials in children and adolescents. In: Prien RF, Robinson DS, eds. Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines. New York, NY: Raven Press; 1994:501-546.
20. Posner K, Oquendo M, Stanley B, et al. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007;164:1035-1043.
21. Foglia JP, Sorisio D, Kirshner MA, et al. Quantitative determination of paroxetine in plasma by high-performance liquid chromatography and ultraviolet detection. J Chromotogr Biomed Appl. 1997;693: 147-151.
22. Foglia JP, Pollock BG, Kirshner MA, et al. Plasma levels of citalopram enantiomers and metabolites in elderly patients. Psychopharmacol Bull. 1997;33:109-112.
23. Jin Y, Pollock BG, Frank E, et al. The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. J Clin Pharmacol. 2009;49:176-184.
24. Booth BP, Gobburu JVS. Considerations in analyzing single-trough concentrations using mixed-effects modeling. J Clin Pharmacol. 2003;43:1307-1315.
25. Preskorn SH. Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors. Caddo, OK: Professional Communications, Inc.; 1996.
26. Thase ME, Shelton RC, Khan A. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. J Clin Psychopharmacol. 2006;26:250-258.